Khalid Islam

Khalid Islam founded Prev AbR LLC in 2010, Ki Consulting AG in 2009, where he worked as Chairman, Sirius Healthcare Partners GmbH in 2009, where he is working as Partner from 2009, Life Sciences Management GmbH in 2014, where he is working as Managing Director from 2014, and Gain Therapeutics, Inc. in 2017, where he is working as Chairman from 2025.
Dr. Islam also founded BioAim LLC.
Dr. Islam also currently works at Fennec Pharmaceuticals, Inc., as Chairman from 2015, Minoryx Therapeutics SL, as Chairman from 2016, GT Gain Therapeutics SA, as Chairman, and Kurma Biofund FCPR, as Advisor.
Dr. Islam also formerly worked at Gentium Srl, as Chairman & Chief Executive Officer from 2009 to 2014, Arpida AG, as President, Chief Executive Officer & Director from 2000 to 2008, Caerus Consulting AS, as Chairman from 2010 to 2014, Arpida, Inc., as Chairman from 2006 to 2009, PCOVERY ApS, as Chairman from 2013 to 2015, Adenium Biotech ApS, as Chairman, Adenium AB, as Chairman, Immunomedics, Inc., as Independent Director from 2017 to 2020, AGC Biologics SpA, as Director from 2014 to 2016, OxThera AB, as Director from 2014 to 2017, Rheoscience A, as Director, KDventures AB, as Director from 2015 to 2017, Processa Pharmaceuticals, Inc., as Director from 2020 to 2022, Elion Oncology, Inc., as Director, the University of Milan, as Professor, Marion Merrell Dow (Europe) AG, as Head-Biotechnology, and Hoechst Marion Roussel Group, as Team Leader & Manager-Alliance.
Dr. Islam received his doctorate degree in 1983 from Imperial College London and undergraduate degree in 1977 from Chelsea College.